In a report released yesterday, Akash Tewari from Jefferies maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price ...

When investors are paying such high price tags for a stock, expectations are high, and any kind of miss can result in a steep ...

DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating on January 21.Invest with Confidence: Follow ...

An Alphabet-backed startup is poised to begin clinical trials of its first artificial intelligence-designed drug by year-end.

"Given the fact that there are states, counties, cities, school districts, pension funds, and other plaintiffs from all over ...

Patent law specialist Hoffmann Eitle is taking over the Dusseldorf office of boutique KSVR (König - Szynka - Tilmann - von Renesse) next month. KSVR partners Gregor König, Dorothea von Renesse and ...

Viking Therapeutics investors face challenges as stock plummets, cash runway helps but betting on early stage biopharma ...

Ozempic was one of the 15 drugs selected for the 2027 Medicare drug price negotiation program three days before ...

The government is expected to pay lower prices for Ozempic and Wegovy starting in 2027. The Trump administration will decide ...

This past year featured key developments in the prescription drug policy area, including the implementation of significant ...

WASHINGTON >> Current laws and regulations are not enough to protect Americans from the risks of compounded versions of popular weight loss drugs, especially those bought online, outgoing U.S. Food ...

N-Power Medicine, backed by Merck GHI, announced the acquisition of Syapse Holdings. Samsung Biologics and LigaChem extended their ADC services deal. Publicis Worldwide merged with Leo Burnett to form ...